SMT202400418T1 - Inibitori a piccola molecola di chinasi che induce nf-κb - Google Patents

Inibitori a piccola molecola di chinasi che induce nf-κb

Info

Publication number
SMT202400418T1
SMT202400418T1 SM20240418T SMT202400418T SMT202400418T1 SM T202400418 T1 SMT202400418 T1 SM T202400418T1 SM 20240418 T SM20240418 T SM 20240418T SM T202400418 T SMT202400418 T SM T202400418T SM T202400418 T1 SMT202400418 T1 SM T202400418T1
Authority
SM
San Marino
Prior art keywords
small molecule
molecule inhibitors
inducing kinase
kinase
inducing
Prior art date
Application number
SM20240418T
Other languages
English (en)
Italian (it)
Inventor
Wenying Chai
Kevin D Kreutter
J Kent Barbay
Wendy Eccles
Michael D Hack
Aaron T Herrmann
William M Jones
Paul J Krawczuk
Alec D Lebsack
Daniel J Pippel
Alexander R Rovira
Ronald L Wolin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SMT202400418T1 publication Critical patent/SMT202400418T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20240418T 2019-05-31 2020-05-29 Inibitori a piccola molecola di chinasi che induce nf-κb SMT202400418T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US201962907833P 2019-09-30 2019-09-30
EP20733688.4A EP3976597B1 (en) 2019-05-31 2020-05-29 Small molecule inhibitors of nf-kb inducing kinase
PCT/EP2020/065024 WO2020239999A1 (en) 2019-05-31 2020-05-29 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

Publications (1)

Publication Number Publication Date
SMT202400418T1 true SMT202400418T1 (it) 2024-11-15

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240418T SMT202400418T1 (it) 2019-05-31 2020-05-29 Inibitori a piccola molecola di chinasi che induce nf-κb

Country Status (37)

Country Link
US (3) US11254673B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (2) EP4467199A3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (2) JP7547387B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (1) KR20220027871A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (2) CN118908957A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (1) AU2020282005A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (1) BR112021023796A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA3143350A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CL (1) CL2021003142A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CO (1) CO2021017838A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CR (1) CR20210587A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (1) DK3976597T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DO (1) DOP2021000244A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EC (1) ECSP21093623A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (1) ES2989387T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
FI (1) FI3976597T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (1) HRP20241352T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (1) HUE068694T2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (1) IL288387B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JO (1) JOP20210318A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LT (1) LT3976597T (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MA (1) MA56038B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MD (1) MD3976597T2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (1) MX2021014679A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MY (1) MY205653A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PE (1) PE20220768A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PH (1) PH12021553011A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (1) PL3976597T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (1) PT3976597T (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RS (1) RS66105B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SA (1) SA521430960B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SG (1) SG11202112994WA (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (1) SI3976597T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SM (1) SMT202400418T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TW (2) TW202517638A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UY (1) UY38721A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2020239999A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3976597T2 (ro) * 2019-05-31 2025-01-31 Janssen Pharmaceutica Nv Inhibitori cu molecula mică ai kinazei care induce NF-kB
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN119546602A (zh) * 2022-05-11 2025-02-28 詹森药业有限公司 作为NFκB诱导激酶的抑制剂的吡咯烷酮衍生物
JP2025516559A (ja) * 2022-05-11 2025-05-30 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｆ－カッパｂ誘導性キナーゼの阻害剤としてのピロリジオン（ｐｙｒｒｏｌｉｄｉｏｎｅ）誘導体
TW202438059A (zh) 2022-12-22 2024-10-01 德商百靈佳殷格翰國際股份有限公司 Her2抑制劑之結晶形式
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
US20250122206A1 (en) 2023-07-28 2025-04-17 Boehringer Ingelheim International Gmbh Process for the manufacture of a her2 inhibitor

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
TW200605886A (en) * 2004-08-03 2006-02-16 Wyeth Corp Indazoles useful in treating cardiovascular diseases
JP4964780B2 (ja) 2004-11-12 2012-07-04 スタッツ・チップパック・インコーポレイテッド ワイヤボンド相互接続、半導体パッケージ、および、ワイヤボンド相互接続の形成方法
MX2010013920A (es) * 2008-06-26 2011-02-21 Amgen Inc Alcoholes alquinilicos como inhibidores de cinasas.
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
KR20130133051A (ko) 2011-03-16 2013-12-05 에프. 호프만-라 로슈 아게 6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도
AR089999A1 (es) * 2012-02-17 2014-10-01 Hoffmann La Roche Compuestos triciclicos y metodos para el uso de los mismos
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
RU2016110021A (ru) * 2013-08-22 2017-09-27 Ф. Хоффманн-Ля Рош Аг Алкиниловые спирты и способы их применения
RU2016110016A (ru) * 2013-08-22 2017-09-27 Ф. Хоффманн-Ля Рош Аг Алкиниловые спирты и способы их применения
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
AU2015334915B2 (en) 2014-10-23 2019-09-19 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as NIK inhibitors
BR112017007715B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V. Derivados de tienopirimidina como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende
WO2016062791A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazole derivatives as nik inhibitors
CN107074855B (zh) 2014-10-23 2019-11-05 詹森药业有限公司 作为nik抑制剂的新的化合物
CN107406427A (zh) 2015-02-25 2017-11-28 豪夫迈·罗氏有限公司 炔基醇及其使用方法
DK3405196T3 (en) 2016-01-22 2020-03-09 Janssen Pharmaceutica Nv Nye substituerede cyanoindolinderivater som nik-inhibitorer
JP6916796B2 (ja) 2016-01-22 2021-08-11 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体
JP6936815B2 (ja) 2016-06-30 2021-09-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
EP3504192B1 (en) * 2016-08-24 2022-04-06 F. Hoffmann-La Roche AG 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
JP7140751B2 (ja) 2016-08-24 2022-09-21 エフ．ホフマン－ラ ロシュ アーゲー ２－アザビシクロ［３．１．０］ヘキサン－３－オン誘導体及び使用方法
AU2018297592B2 (en) 2017-07-06 2021-12-16 Janssen Pharmaceutica Nv New substituted azaindoline derivatives as NIK inhibitors
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
BR112021022099A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
EP3976194A2 (en) 2019-05-31 2022-04-06 Ikena Oncology, Inc. Tead inhibitors and uses thereof
JOP20210293A1 (ar) 2019-05-31 2023-01-30 Sage Therapeutics Inc ستيرويدات ذات فعالية عصبية وتركيبات منها
MD3976597T2 (ro) * 2019-05-31 2025-01-31 Janssen Pharmaceutica Nv Inhibitori cu molecula mică ai kinazei care induce NF-kB
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators

Also Published As

Publication number Publication date
US11254673B2 (en) 2022-02-22
CR20210587A (es) 2022-02-11
MA56038A (fr) 2022-04-06
HRP20241352T1 (hr) 2024-12-20
BR112021023796A2 (pt) 2022-02-08
UY38721A (es) 2020-11-30
JP7547387B2 (ja) 2024-09-09
JOP20210318A1 (ar) 2023-01-30
EP3976597B1 (en) 2024-08-28
IL288387A (en) 2022-01-01
ECSP21093623A (es) 2022-01-31
CA3143350A1 (en) 2020-12-03
LT3976597T (lt) 2024-10-10
CN114222737B (zh) 2024-07-26
TW202110842A (zh) 2021-03-16
US20210300918A1 (en) 2021-09-30
MX2021014679A (es) 2022-04-06
JP2022534302A (ja) 2022-07-28
AU2020282005A1 (en) 2021-12-23
RS66105B1 (sr) 2024-11-29
US11827634B2 (en) 2023-11-28
MA56038B1 (fr) 2024-11-29
FI3976597T3 (fi) 2024-09-25
DK3976597T3 (da) 2024-09-09
PE20220768A1 (es) 2022-05-16
PL3976597T3 (pl) 2024-12-16
SA521430960B1 (ar) 2024-11-12
CO2021017838A2 (es) 2022-01-17
IL288387B1 (en) 2025-09-01
TWI850390B (zh) 2024-08-01
PH12021553011A1 (en) 2022-11-07
CN118908957A (zh) 2024-11-08
EP3976597A1 (en) 2022-04-06
DOP2021000244A (es) 2022-04-18
ES2989387T3 (es) 2024-11-26
WO2020239999A1 (en) 2020-12-03
EP4467199A3 (en) 2025-03-05
KR20220027871A (ko) 2022-03-08
PT3976597T (pt) 2024-10-22
CL2021003142A1 (es) 2022-08-19
CN114222737A (zh) 2022-03-22
MD3976597T2 (ro) 2025-01-31
HUE068694T2 (hu) 2025-01-28
SG11202112994WA (en) 2021-12-30
US20240199605A1 (en) 2024-06-20
US20230080834A1 (en) 2023-03-16
EP4467199A2 (en) 2024-11-27
SI3976597T1 (sl) 2024-11-29
MY205653A (en) 2024-11-02
TW202517638A (zh) 2025-05-01
JP2024167319A (ja) 2024-12-03

Similar Documents

Publication Publication Date Title
IL288387B1 (en) Small molecule inhibitors of NF-kB factor kinase
IL322454A (en) ras inhibitors
IL292643A (en) ras inhibitors
IL320513A (en) RAS inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
ZA202203770B (en) Pharmaceutical combination of prmt5 inhibitors
SI3700902T1 (sl) Inhibitorji trpc6
EP3927700A4 (en) KINAS INHIBITORS
IL264593A (en) Medicinal preparations containing akt protein kinase inhibitors
IL279314A (en) Small molecule inhibitors of the JAK family of kinases
IL313548A (en) MET kinase inhibitors
EP3999064A4 (en) Inhibitors of tyrosine kinase
IL281599A (en) TYK2 kinase inhibitors
IL277869A (en) Substituted propanamides as nuclease inhibitors
SG10201909596RA (en) Synthesis of Tyrosine Kinase Inhibitors
HK40119602A (en) Small molecule inhibitors of nf-kb inducing kinase
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
GB201807845D0 (en) Kinase Inhibitors
HK40099704A (en) Small molecule inhibitors of nf-kb inducing kinase
GB201914388D0 (en) Kinase inhibitors
HK40075155A (en) Inhibitors of tyrosine kinase
HK40048146A (en) Tyk2 kinase inhibitors
HK40015193A (en) Glucuronide prodrugs of janus kinase inhibitors